The challenges in paediatric pulmonary arterial hypertension

European Respiratory Review

Volumn 23, Issue 134, 2014, Pages 498-504

  Beghetti, Maurice ^a   Berger, Rolf M F ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR AGONIST; PROSTACYCLIN; PROSTANOID; SILDENAFIL; TADALAFIL; ANTIHYPERTENSIVE AGENT;

CLINICAL FEATURE; CLINICAL STUDY; DRUG EFFICACY; FUNCTIONAL STATUS; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; LUNG BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; ADOLESCENT; AGE; BIOASSAY; CHILD; DISEASE MANAGEMENT; DOSE RESPONSE; EXERCISE TEST; HYPERTENSION, PULMONARY; INFANT; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; INFANT; TREATMENT OUTCOME;

EID: 84914158054     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007714     Document Type: Review

References (43)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S
2. Beghetti M, Berger RM, Schulze-Neick I, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J 2013; 42: 689-700.
3. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012; 21: 8-18.
4. van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124: 1755-1764.
5. Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379: 537-546.
6. van Loon RL, Roofthooft MT, Delhaas T, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 2010; 106: 117-124.
7. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96: 1401-1406.
8. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol 2005; 29: 8-14.
9. del Cerro MJ, Abman S, Diaz G, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011; 1: 286-298.
10. Simonneau G, Gatzoulis M, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D34-D41
11. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
12. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
13. Schulze-Neick I, Beghetti M. Issues related to the management and therapy of paediatric pulmonary hypertension. Eur Respir Rev 2010; 19: 331-339.
14. Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995; 25: 466-474.
15. Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125: 113-122.
16. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009; 95: 312-317.
17. Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014; 35: 716-724.
18. Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D117-D126
19. Lammers AE, Diller GP, Odendaal D, et al. Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension. Arch Dis Child 2011; 96: 141-147.
20. Lammers AE, Munnery E, Hislop AA, et al. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 2010; 142: 159-165.
21. Adatia I, Haworth SG, Wegner M, et al. Clinical trials in neonates and children: report of the pulmonary hypertension academic research consortium pediatric advisory committee. Pulm Circ 2013; 3: 252-266.
22. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135: 21-26.
23. Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 2012; 7: 259-267.
24. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63: 321-327.
25. Ploegstra M-J, Douwes JM, Roofthooft MTR, et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J 2014; 44: 1616-1626.
26. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
27. Douwes JM, van Loon RL, Hoendermis ES, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J 2011; 32: 3137-3146.
28. Colvin KL, Dufva MJ, Delaney RP, et al. Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate. Front Pediatr 2014; 2: 7.
29. Jone PN, Hinzman J, Wagner BD, et al. Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension. J Am Soc Echocardiogr 2014; 27: 172-178.
30. Kirkpatrick EC. Echocardiography in pediatric pulmonary hypertension. Paediatr Respir Rev 2013; 14: 157-164.
31. Di Maria JM, Younoszai AK, Mertens L, et al. RV stroke work in children with pulmonary arterial hypertension: estimation based on invasive haemodynamic assessment and correlation with outcomes. Heart 2014; 100: 1342-1347.
32. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948-955.
33. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatric Pulmonol 2013; 48: 27-34.
34. Siehr SL, Ivy DD, Miller-Reed K, et al. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. J Heart Lung Transplant 2013; 32: 546-552.
35. Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatmentnaïve pediatric pulmonary arterial hypertension. Circulation 2014; 129: 1914-1923.
36. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324-334.
37. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012; 33: 683-688.
38. Zijlstra WM, Douwes JM, Rosenzweig EB, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol 2014; 63: 2159-2169.
39. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169.
40. Levy M, Celermajer DS, Bourges-Petit E, et al. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 2011; 158: 584-588.
41. Baruteau AE, Serraf A, Lévy M, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: longterm results. Ann Thorac Surg 2012; 94: 817-824.
42. Berger RM. Pulmonary hypertension: smaller kids, smaller steps. Lancet Respir Med 2014; 2: 348-350.
43. Taylor CJ, Derrick G, McEwan A, et al. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 2007; 98: 657-661.